Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

If you're curious about the latest advancements in addiction treatment, this episode of 'This Week in Addiction Medicine' is a must-listen. The focus is on a fascinating study published in JAMA Psychiatry that examines the effects of semaglutide, a GLP-1 receptor agonist, on alcohol use disorder (AUD). The study reveals that low-dose semaglutide can significantly reduce alcohol consumption and cravings over a nine-week period.

It's not just about alcohol; semaglutide also showed promise in reducing cigarette use among participants who smoked. This episode dives into the details of the clinical trial, highlighting the potential of incretin therapies for treating AUD. Alongside this, the episode touches on other critical issues such as online gambling policies in Europe, the impact of buprenorphine on fentanyl users, and racial disparities in opioid use disorder treatments among pregnant individuals.

Each segment is packed with essential information and expert analysis that can benefit anyone interested in addiction medicine. With Zach Caruso at the helm, the podcast balances scientific rigor with an engaging presentation style, making complex topics accessible and interesting. Whether you're a healthcare professional or someone personally affected by addiction, you'll find valuable insights and actionable information here. Don't miss out on these important discussions that could shape the future of addiction treatment.